Home
Disease Knowledge Center Drug Hub Monographs Drug Interactions Pregnancy Drug Safety Drug Recalls & Alerts OTC Navigator
Virtual Simulators Hub Clinical Cases Simulator Nutrition & Macro Calculator
Questo Insights Global Opportunities Hub AI Research Assistant Citation & Reference Generator Scholarships & Essay Planner Visa & Mobility Navigator English Assessment Test
Verified Jobs Board Pharmacy Clearance Pharmacies Directory
Practice Quizzes STEM Academy Toolkits
Medical Case Donations Opportunity Crowdfunding Community Forums Courses Academy
Back to Safety Checker

Ondansetron

5-HT3 Receptor Antagonist Antiemetic

FDA Category B (No Fetal Risk in Human/Animal Studies) FDA Category B & ACOG Endorsed
Safe / Preferred for Hyperemesis Gravidarum

Ondansetron (Zofran) is a 5-HT3 receptor antagonist widely prescribed and endorsed by ACOG for moderate-to-severe pregnancy-induced nausea and hyperemesis gravidarum when first-line oral antiemetics (doxylamine/pyridoxine) are insufficient.

Medical Disclaimer: This report is for educational and informational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making any medication decisions during pregnancy.
Pregnancy Summary
Clinical overview for pregnancy

Ondansetron is FDA Category B. Extensive epidemiological cohorts (>1.8 million pregnancies) demonstrate safety with no elevated risk of major structural birth defects.

Trimester Safety Timeline
Safety profile across all three trimesters
1st Trimester
Weeks 1 – 12
Safe / Indicated

First-line for severe nausea/vomiting (hyperemesis gravidarum). Prevents severe maternal dehydration and electrolyte imbalance.

2nd Trimester
Weeks 13 – 27
Safe

Safe for ongoing symptoms. Maintains maternal nutritional intake.

3rd Trimester
Weeks 28 – Birth
Safe

Safe through delivery.

Placental Transfer
Does this medication cross the placenta?
Crosses Placenta
Yes
Transfer Extent
Moderate (Crosses placental barrier in small physiological amounts)

Minimal fetal accumulation. No adverse impact on fetal organogenesis.

Fetal Risk Assessment
Potential effects on the developing fetus
No Increased Risk of Major Teratogenicity

Large prospective studies (>1,800,000 pregnant women) show no overall increase in major birth defects or oral clefts.

Maternal Risk Assessment
Potential maternal side effects during pregnancy
Constipation & Mild Headache

Constipation is the most common side effect. Manage with fluid intake and dietary fiber.

Clinical Recommendation
Professional prescribing guidance
Preferred Option for Hyperemesis Gravidarum

Prescribe 4–8 mg orally or IV every 8 hours for severe nausea/vomiting unresponsive to first-line measures.

If Already Taken
"I took this before knowing I was pregnant"
1
Reassurance

Ondansetron is safe and effectively protects against severe maternal dehydration.

Pregnancy Monitoring Protocol
Recommended follow-up and surveillance
Clinical Monitoring
  • Monitor maternal hydration status and electrolytes
  • Monitor bowel movements (prevent constipation)
Safer Alternatives
Active ingredients with better pregnancy safety profiles
metoclopramide
Alternative safe prokinetic antiemetic (Category B).
Safe Alternative
Professional Clinical Notes
Key prescribing considerations and clinical pearls
  • ACOG Practice Bulletin #189: Ondansetron is an effective option for hyperemesis gravidarum.
Patient-Friendly Explanation
In simple, easy-to-understand language
Easy to Understand

Ondansetron (Zofran) is safe to take during pregnancy to treat severe nausea and vomiting. Stopping severe vomiting is important to keep you and your baby hydrated.

Frequently Asked Questions
Common questions about Ondansetron in pregnancy

Yes, Zofran is Category B and widely prescribed for morning sickness and hyperemesis gravidarum.

Evidence Level
Quality of available safety data
FDA Category B & ACOG Endorsed

Backed by FDA PLLR Category B designation, ACOG Practice Bulletins, and 1.8M patient cohorts.

References & Primary Sources
Official U.S. Food & Drug Administration (FDA) PLLR & ACOG Clinical Database
All pregnancy safety evaluations, risk categories, and drug monographs are compiled directly from U.S. FDA Pregnancy and Lactation Labeling Rule (PLLR) standards and approved FDA prescribing labels.
  1. 1
    U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
  2. 2
    FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
  3. 3
    ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
  4. 4
    Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition
Search Another Medication

System Notice

Confirm Action